---
figid: PMC4659440__tog-suppl.1-2015-013f5
figlink: /pmc/articles/PMC4659440/figure/f5-tog-suppl.1-2015-013/
number: Figure 5
caption: 'Functional crosstalk of HGF-MET signaling pathway with EGFR and VEGFR signaling
  pathway.Notes: The anticancer treatment with EGFR antibodies (cetuximab, panitumumab)
  or EGFR TKIs (gefitinib, erlotinib) leads to MET amplification with subsequent activation
  of PI3K-AKT signaling. The resistance can be prevented by dual inhibition of EGFR
  and MET. Similarly, MET-HGF signaling pathway activation help evade VEGFR inhibition
  induced by bevacizumab, sunitinib or pazopanib and dual inhibition with VEGFR and
  MET inhibitor might overcome the resistance to anticancer treatment.'
pmcid: PMC4659440
papertitle: c-Met as a Target for Personalized Therapy.
reftext: Ingrid Garajov√°, et al. Transl Oncogenomics. 2015;7(Suppl 1):13-31.
pmc_ranked_result_index: '38911'
pathway_score: 0.9670447
filename: tog-suppl.1-2015-013f5.jpg
figtitle: c-Met as a Target for Personalized Therapy.
year: '2015'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4659440__tog-suppl.1-2015-013f5.html
  '@type': Dataset
  description: 'Functional crosstalk of HGF-MET signaling pathway with EGFR and VEGFR
    signaling pathway.Notes: The anticancer treatment with EGFR antibodies (cetuximab,
    panitumumab) or EGFR TKIs (gefitinib, erlotinib) leads to MET amplification with
    subsequent activation of PI3K-AKT signaling. The resistance can be prevented by
    dual inhibition of EGFR and MET. Similarly, MET-HGF signaling pathway activation
    help evade VEGFR inhibition induced by bevacizumab, sunitinib or pazopanib and
    dual inhibition with VEGFR and MET inhibitor might overcome the resistance to
    anticancer treatment.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MET
  - AKT2
  - RAF1
  - MTOR
  - PIK3CA
  - BRAF
  - AKT3
  - AKT1
  - HGF
  - MAP2K1
  - MAP2K2
  - FLT4
  - PIK3R6
  - PIK3R5
  - EGF
  - NRAS
  - PIK3R4
  - FLT1
  - ARAF
  - PIK3CB
  - EGFR
  - PIK3R3
  - KRAS
  - HRAS
  - VGF
  - KDR
  - PIK3CG
  - PIK3CD
  - pazopanib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: VGF
  symbol: VGF
  source: hgnc_symbol
  hgnc_symbol: VGF
  entrez: '7425'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals:
- word: pazopanib
  source: MESH
  identifier: C516667
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
